Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
- Conditions
- First Posted Date
- 2004-01-23
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- International Collaborative Cancer Group
- Target Recruit Count
- 4400
- Registration Number
- NCT00003418
- Locations
- 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇫🇷Centre Antoine Lacassagne, Nice, France
🇬🇧Charing Cross Hospital, London, England, United Kingdom
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-11-17
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 46
- Registration Number
- NCT00073073
- Locations
- 🇺🇸
Lombardi Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 2672
- Registration Number
- NCT00066703
- Locations
- 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 98
- Registration Number
- NCT00066586
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
🇨🇦Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇨🇦Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
Premenopausal Endocrine Responsive Chemotherapy Trial
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 29
- Registration Number
- NCT00066807
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭Kantonsspital - St. Gallen, St. Gallen, Switzerland
🇮🇹Centro di Riferimento Oncologico - Aviano, Aviano, Italy
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 3066
- Registration Number
- NCT00066690
- Locations
- 🇺🇸
Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Finley Hospital, Dubuque, Iowa, United States
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 7576
- Registration Number
- NCT00066573
- Locations
- 🇨🇦
Stronach Regional Health Centre at Southlake, Newmarket, Ontario, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Credit Valley Hospital, Mississauga, Ontario, Canada
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-07-23
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 694
- Registration Number
- NCT00065325
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer
- First Posted Date
- 2003-07-01
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 5
- Registration Number
- NCT00031889
- Locations
- 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭Spitalzentrum Biel, Biel, Switzerland
🇨🇭Ospedale Beata Vergine, Mendrisio, Switzerland
Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 342
- Registration Number
- NCT00002777
- Locations
- 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇬🇧Western General Hospital, Edinburgh, Scotland, United Kingdom
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.